Replies to post #115288 on Amarin Corp Plc (AMRN)

[ralphey]

AS I have posted here numerous times this is a grievous flaw in the study design. Statin intolerant individuals should have been included as a subset . The likelihood of success in this group would be greater and reveal effectiveness if the compound is only marginally beneficial - opening up a huge potential market. With the current study design if the compound is only marginally effective it is possible that no benefit is revealed - shutting down a huge potential market ..... This is an inexcusable flaw in study design